ClinicalTrials.gg
RecruitingNCT06858397Updated Nov 4, 2025

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

A Phase 1/2 interventional study of HM15421/GC1134A in Fabry Disesase, sponsored by GC Biopharma Corp. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by GC Biopharma Corp · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

02

Conditions studied

  • Fabry Disesase
03

In context

Lead sponsor

GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be ≥ 18 years of age or age considered as adult in the respective country at the time of signing the .
  2. Documented diagnosis of FD with clinical symptoms.
  3. Females: historical genetic test results based on identification of pathogenic or likely pathogenic GLA variant of FD.
  4. Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN in plasma=3.2 nmol/hr/mL, LLN in leucocytes=32 nmol/hr/mg/protein).
  5. Patients who are naive or have not received FD therapy including therapy for FD within the past 6 months prior to screening and have negative ADA testing at screening.
  6. Estimated (eGFR) ≥ 60 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  7. Plasma lyso-Gb3 levels greater than 1.5 times the (ULN).
  8. Male participants:

    • Male participants are eligible to participate if they agree to the following during the study treatment period:
    • Refrain from donating sperm,

    PLUS either:

    • Be abstinent from heterosexual intercourse with a woman of (WOCBP) as their preferred and usual lifestyle (abstinent on a longterm and persistent basis) and agree to remain abstinent, OR
    • Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person,
    • In addition to male condom, use of highly effective method of may be considered in WOCBP partners of male participants.
  9. Female participants:

    • Female participants are eligible to participate if they are not pregnant or breastfeeding, and at least 1 of the following conditions applies:

      • Is not a WOCBP, OR
      • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year), preferably with low user dependency, starting at least one menstrual cycle before first study drug administration and continuing for at least 30 days after the end of systemic exposure of the study drug and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study drug.
      • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study drug.
      • If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • Women whose status is recent, may perform additional follicle stimulating hormone (FSH) testing.

    Informed Consent

  10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, planning to become pregnant during the study, or are breast feeding.
  2. History of dialysis or renal transplantation.
  3. CKD stage ≥ 3.
  4. History of acute kidney injury within 12 months prior to screening, including specific kidney diseases (eg, acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (eg, ischemia, toxic injury); as well as extrarenal pathology (eg, prerenal azotemia, and acute postrenal obstructive nephropathy).
  5. Urine protein to creatinine ratio (UPCR) > 0.5 g/g and not treated with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
  6. Known history of to any ingredient in the product and to Gadolinium contrast agent that is not managed by the use of premedication.
  7. Cardiovascular event (myocardial infarction, unstable angina) within 6 months before screening.
  8. Congestive heart failure (NYHA) Class IV
  9. History of stroke.
  10. Pacemaker or other for magnetic resonance imaging (MRI) scanning.
  11. Angiotensin converting enzyme inhibitor or ARB therapy initiated or dose changed in the 4 weeks prior to screening.
  12. Patients who received investigational gene therapy for FD.
  13. Participation in other studies involving study drugs within 4 weeks prior to study entry and/or during study participation.
  14. Participating in interventional study or using compassionate access product for FD. Participants who have participated in interventional trials for conditions not related to FD should be enrolled after the adequate wash out period is over, which is 5 half-lives or 30 days whichever is longer.
  15. Presence of (HIV) and/or active (acute or chronic) and/or infections.
  16. Presence of any medical, emotional, behavioral, or psychological condition that, in the judgment of the Investigator and/or Medical Monitor, would interfere with the participant's compliance with the requirements of the study.
  17. Participants who may have history of deliberate self-harm or suicidal ideation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Low dose

    Drug: HM15421/GC1134A

  • Experimental
    Cohort 2

    Mid dose

    Drug: HM15421/GC1134A

  • Experimental
    Cohort 3

    High dose

    Drug: HM15421/GC1134A

Interventions

  • DrugHM15421/GC1134A

    SC

06

What researchers measure

Primary outcomes

  1. Incidences and characteristics of adverse events

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Maximum serum concentration (Cmax)

    PK parameter

    Time frame: Up to 48 weeks

  2. Time to reach maximum serum concentration (Tmax)

    PK parameter

    Time frame: Up to 48 weeks

  3. Trough serum concentration (Ctrough)

    PK parameter

    Time frame: Up to 48 weeks

  4. Area under the concentration-time curve in one dosing interval (AUC0-tau)

    PK parameter

    Time frame: Up to 48 weeks

  5. Terminal elimination half-life (t1/2)

    PK parameter

    Time frame: Up to 48 weeks

  6. Apparent clearance at steady state (CLss/F)

    PK parameter

    Time frame: Up to 48 weeks

  7. Apparant volume of distribution at steady state during the terminal phase (Vss/F)

    PK parameter

    Time frame: Up to 48 weeks

  8. Plasma Lyso-Gb3 level

    PD parameter

    Time frame: Up to 48 weeks

  9. Plasma Gb3 level

    PD parameter

    Time frame: Up to 48 weeks

  10. Urine Lyso-Gb3 level

    PD Parameter

    Time frame: Up to 48 weeks

  11. Urine Creatinine level

    PD parameter

    Time frame: Up to 48 weeks

  12. Urine Albumin level

    PD parameter

    Time frame: Up to 48 weeks

  13. Total Urine Protein Level

    PD parameter

    Time frame: Up to 48 weeks

  14. Urine Protein to Creatinine Ratio

    PD parameter

    Time frame: Up to 48 weeks

  15. Urine Albumin to Creatinine Ratio

    PD parameter

    Time frame: Up to 48 weeks

  16. Change in eGFR

    PD parameter

    Time frame: Up to 48 weeks

  17. Change in kidney Gb3 accumulation using the quantative Barisoni Lipid Inclusion Scoring System

    PD parameter

    Time frame: Up to 48 weeks

07

Study locations

10 of 10 sites recruiting
  • David Geffen School of Medicine UCLA, UCLA Health
    Los Angeles, California 90095, United States
    Recruiting
    • Anjay Rastogi, MD · Principal investigator
  • University of Kansas School of Medicine
    Kansas City, Kansas 66160-8500, United States
    Recruiting
    • Ahmad M. Tuffaha, MD · Principal investigator
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Chester B. Whitley, MD · Principal investigator
  • Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
    Recruiting
    • Robert J. Hopkin, MD · Principal investigator
  • University of Pittsburgh Medical Center Children's Hoispital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Damara Ortiz, MD · Principal investigator
  • Lysosomal and Rare Disorders Research and Treatment Center
    Fairfax, Virginia 22030, United States
    Recruiting
    • Ozlem Goker-Alpan, MD · Principal investigator
  • Centro Medico IPAM
    Rosario, Santa Fe Province S2000, Argentina
    Recruiting
    • Sebastian Jaurretche, MD · Principal investigator
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1199ABB, Argentina
    Recruiting
    • Marcelo Rugiero, MD · Principal investigator
  • Pusan National University Children's Hospital in Yangsan
    Yangsan, Gyeongsangnam-do 50612, South Korea
    Recruiting
    • Chong Kun Cheon, MD · Principal investigator
  • Yonsei University, College of Medicine
    Seoul, 03722, South Korea
    Recruiting
    • Geu-Ru Hong, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Mar 5, 2025
StartActual
May 14, 2025
Primary completionEst.
Aug 30, 2028
CompletionEst.
Aug 30, 2028
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06858397
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
May 14, 2025
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Nov 4, 2025

Study contacts

GC Biopharma
Contact
GC1134A@gccorp.com
+82-031-260-9300

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion